HCPCS Code J1572: Flebogamma immune globulin billing guide

Key takeaways

HCPCS Code J1572 covers injection of immune globulin (Flebogamma or Flebogamma DIF), intravenous, non-lyophilized, billed per 500 mg.

One billing unit equals 500 mg administered. A 5 g dose is 10 units, and a 30 g dose is 60 units.

Medicare Part B covers J1572 for the medically necessary indications listed in CMS Article A57778, and the NDC is required on every claim.

Flebogamma ships in single-dose vials, so each claim carries modifier JW for discarded units or JZ when nothing is discarded.

Practice management software like Pabau keeps the order, diagnosis, and infusion record on one patient file, so J1572 claims are easier to support.

HCPCS Code J1572: full description and code details

HCPCS Code J1572 covers injection of immune globulin (Flebogamma or Flebogamma DIF), intravenous, non-lyophilized, in 500 mg increments. Infusion practices use it to bill the drug itself whenever a Grifols IVIG product is given on an outpatient basis. This guide covers the descriptor, the unit math, Medicare coverage criteria, the supporting ICD-10-CM diagnosis codes, and how the payment rate is set.

HCPCS Code J1572 is a Level II J-code maintained by the Centers for Medicare and Medicaid Services (CMS) under the Healthcare Common Procedure Coding System. J-codes cover drugs and biologicals given by injection. They are required on outpatient Medicare claims when the drug cost is billed separately from the professional or facility fee.

Flebogamma and Flebogamma DIF: drug overview

Flebogamma and Flebogamma DIF are intravenous immune globulin (IVIG) products manufactured by Grifols. Both contain purified human immunoglobulin G (IgG) antibodies pooled from thousands of plasma donors, delivered as a liquid ready-to-infuse solution. This distinguishes them from lyophilized (powder-form) IVIG products, which require reconstitution before administration and carry different HCPCS codes.

The “DIF” suffix in Flebogamma DIF denotes an additional depth-filtration purification step. This process reduces the risk of pathogen transmission without altering the IgG content or therapeutic mechanism. For billing purposes, both formulations are captured under HCPCS Code J1572 and coded identically. Practices that stock only one formulation do not need a separate code. The descriptor explicitly covers both.

Clinically, Flebogamma treats primary immunodeficiency diseases and the autoimmune or inflammatory conditions where supplemental IgG is medically necessary. The practices billing J1572 most often are IV therapy practices and infusion centers giving IVIG on an outpatient basis. The treating physician’s documented diagnosis decides whether the claim passes Medicare coverage review.

Billing guidelines and unit calculation

The most compliance-sensitive aspect of J1572 is unit calculation. Every 500 mg administered equals one billable unit. Billing teams must convert the prescribed gram dose to milligrams, then divide by 500 to determine units. Rounding rules do not apply. Bill only for the quantity administered and documented in the infusion record.

Worked example: A patient receives a 30 g IVIG infusion of Flebogamma. Converting: 30 g x 1,000 = 30,000 mg. Dividing: 30,000 / 500 = 60 units. The claim line reads: J1572 x 60.

Applied to the doses an infusion practice sees most often, the same arithmetic produces the unit counts below.

Bill type and revenue codes decide whether the claim reaches the right payment system at all. The table below summarizes the standard values for outpatient infusion settings per CMS Article A57778.

The drug and its administration are separate claim lines. Report the infusion time with an administration code, starting at CPT 96365 for the first hour and an add-on code for each additional hour.

Flebogamma is supplied in single-dose vials, which brings the discarded-drug modifiers into play. Report JW on a separate line with the units discarded, or JZ on the J1572 line to attest that nothing was thrown away.

Getting the line right on first submission matters more for IVIG than for almost any other outpatient drug. Practices that run claims software for infusion billing submit from the record that already holds the order and the infusion note. The biller is not reconciling two systems.

Medicare coverage for J1572

Medicare Part B covers J1572 when the service is medically necessary and supported by an appropriate ICD-10-CM diagnosis code. Coverage is governed by CMS Local Coverage Article A57778. That article lists the covered HCPCS codes, supported diagnosis codes, bill type codes, and documentation requirements.

Coverage turns on the documented diagnosis rather than on the drug. The benefit check before each infusion appointment therefore has to confirm the indication as well as active eligibility.

• Covered indications: Primary immunodeficiency diseases, certain autoimmune conditions (e.g., immune thrombocytopenic purpura, Guillain-Barre syndrome), and selected neurological conditions with established medical necessity
• Non-covered indications: Off-label uses that the A57778 diagnosis list does not support, and conditions where Medicare does not recognize IVIG as a covered therapy
• Medical necessity: A physician order establishing the diagnosis and rationale for IVIG therapy is required. The diagnosis must appear on the claim and in the clinical record
• Prior authorization: PA requirements vary by Medicare Advantage plan and commercial payer. Always verify with the specific plan before infusion
• Home infusion: Part B covers immune globulin infused at home for primary immunodeficiency, and the nursing and supply items are billed separately from the drug

One denied IVIG claim can represent thousands of dollars of drug the practice has already bought and infused. That is why J1572 needs a standing appeal process rather than an ad hoc one.

ICD-10 diagnosis codes required for J1572

Every J1572 claim requires at least one supporting ICD-10-CM diagnosis code. Per CMS Article A57778, the following categories represent common covered indications. Practices should source the current, complete list directly from A57778, as CMS updates covered diagnosis codes periodically. Using a diagnosis code not included in A57778 without additional documentation may result in automatic denial.

Verify the complete list of supported diagnosis codes in the current version of CMS Article A57778. Codes outside that list may still be submittable with supporting documentation, but automatic denials are more likely. Document the clinical rationale whenever the diagnosis sits at the edge of the covered indications. Confirm the descriptor against the ICD-10-CM code library before the claim goes out.

Medicare reimbursement basis for J1572 in 2026

Medicare reimburses J1572 under the Part B drug payment methodology, which uses Average Sales Price (ASP) plus 6% (ASP+6%). CMS updates ASP-based rates quarterly. The rate published in one quarter reflects drug sales data from two quarters prior, so the payment amount changes four times per year.

Because IVIG unit costs are high, a small per-unit difference adds up quickly across a patient panel. Set a calendar reminder to cross-check the billing system’s drug fee schedule against the CMS ASP drug pricing files at the start of each quarter.

The Physician Fee Schedule lookup tool does not price J1572. Part B drugs are priced from the quarterly ASP file instead. A rate pulled from the fee schedule search will not match what the MAC pays.

Specific dollar amounts for J1572 are not published here because ASP-based rates change quarterly and vary by MAC locality. Always verify the current rate directly from CMS ASP pricing files before submitting high-value IVIG claims.

Documentation requirements for J1572 claims

Incomplete documentation is the second most common reason for J1572 claim denials, after unit calculation errors. CMS and commercial payers expect a specific set of records to support each IVIG infusion claim. Building a documentation checklist into the infusion workflow before the patient leaves the chair is more reliable than reconstructing records after a denial.

Consistent documentation reduces audit exposure and shortens the appeal when a payer requests records. The requirements below reflect standard CMS guidance for Part B drug claims under A57778.

• Physician order: A signed, dated order naming the IVIG product, dose, frequency, and duration. It must be in the medical record before infusion begins
• Diagnosis documentation: Clinical record establishing the covered ICD-10-CM diagnosis with supporting lab values or clinical findings where applicable (e.g., IgG level for immunodeficiency)
• Infusion administration record: Date, start and stop times, drug name, lot number, NDC, concentration, total volume infused, route, and any adverse reactions
• Quantity administered: Total grams or milligrams documented in the infusion record. It must match the number of J1572 units billed on the claim
• NDC number: Reported in the NDC field on the CMS-1500, or in the 2410 loop of the 837P electronic claim. It is mandatory for all Part B drug claims
• Prior authorization documentation: Copy of the PA approval when the payer requires one. Note the authorization number on the claim
• Superbill: For office-based infusions, a superbill capturing the J1572 line, units, diagnosis code, and NDC in one place simplifies claim submission

Apply the same documentation standard to every IVIG infusion, not only the high-dose ones. Sporadic records create the pattern variation that draws MAC attention during post-payment review.

Related HCPCS codes for immune globulin

J1572 sits among several product-specific immune globulin codes, and none of them substitutes for another. The J157x range is not reserved for immune globulin either, so a neighboring number is no guide to what a code covers. The AAPC HCPCS code reference carries the full descriptor for every code below.

J1575 is the code to keep furthest from J1572. It covers Hyqvia, given subcutaneously with hyaluronidase, and it bills per 100 mg rather than per 500 mg. Cross-coding the two misstates the units by a factor of five in whichever direction the error runs. Match the code to the product name on the purchase invoice and the administration record every time.

Common billing errors and how to avoid them

J1572 claims attract payer scrutiny because IVIG therapy is high-cost and high-volume. Most practices that receive J1572 denials see the same handful of errors repeatedly. Addressing them at the workflow level, rather than the appeal level, is far more cost-effective.

Building denial prevention around these patterns reduces write-offs and shortens the revenue cycle for IVIG infusions. The root cause usually sits upstream of the claim, in intake or in the infusion record.

• Miscalculated units: Billing 1 unit for a 5 g infusion instead of 10 units. Always divide milligrams administered by 500 before entering the unit count.
• Wrong code selection: Using J1569 (Gammagard Liquid) when Flebogamma was administered, or the reverse. Code to the product on the purchase invoice and infusion record.
• Missing or incorrect NDC: Leaving the NDC field blank or entering a wholesaler NDC instead of the manufacturer NDC from the administered vial. The NDC must match the lot dispensed.
• Inadequate diagnosis code linkage: Submitting J1572 with a diagnosis code not listed in A57778 without supporting documentation. Map every J1572 line to a covered ICD-10-CM code before submission.
• Omitted JW or JZ modifier: Billing J1572 from a single-dose vial with neither discarded-drug modifier. Report JW with the wasted units, or JZ to confirm that nothing was discarded.
• Missing prior authorization: Submitting J1572 claims without a PA number when the plan requires it. Confirm PA requirements for each patient’s specific plan, not just the plan type.

Each of these costs far less to catch at the chair than in the appeals queue. A pre-submission check against the infusion record clears most of them in under a minute.

How Pabau keeps J1572 documentation and claims together

Most infusion practices assemble a J1572 claim from three places. The order sits in the chart and the administered quantity sits in the infusion record. The NDC sits on the vial label or in a pharmacy log. The biller reconciles them afterwards.

Pabau, practice management software for infusion and IV therapy practices, holds those pieces on one patient file. The order, the covered diagnosis, and the infusion note with its lot and NDC are all recorded at the chair. The claim is then raised from that same record.

When a MAC asks for records on a J1572 line months later, answering is a lookup rather than a reconstruction. Submitted claims and their status stay attached to the patient, so nobody hunts through a separate billing system to find out what happened.

Keep IVIG orders, notes, and claims together

Pabau gives infusion and IV therapy practices one patient file for the physician order, the infusion record, and the claim. Billers work from the documentation instead of chasing it across systems.

Book a demo

Conclusion

The unit count is where J1572 claims are won or lost. The rest of the line, from the NDC to the diagnosis pointer, can be verified at the chair while the patient is still in it.

So put the check where the information is created rather than where the claim is built. A biller reconstructing a 30 g infusion from a note three days later is guessing. No pricing file records what went into the patient.

Pabau keeps that record in one place for infusion and IV therapy practices. Book a demo to see how it supports J1572 documentation from the physician order through to the submitted claim.

Continue your research

Working out which immune globulin code applies? HCPCS code J1575 covers Hyqvia at 100 mg per unit, the code most often confused with J1572.

Chasing the reason behind a rejected IVIG line? Common denial codes in medical billing maps the frequent CARCs to their root causes and appeal routes.

Want fewer J1572 lines coming back at all? What is a clean claim sets out the fields a payer checks before it accepts a claim.

Checking benefits ahead of a high-cost infusion? Insurance eligibility verification covers the checks that catch a coverage problem before the drug is drawn.

Rebuilding the process after a run of denials? Denial management in healthcare explains how to categorize denials and fix the upstream cause.

Frequently asked questions